famotidine has been researched along with Hyperparathyroidism in 2 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Hyperparathyroidism: A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sato, H | 1 |
| Abe, K | 1 |
| Oshima, N | 1 |
| Kawashima, K | 1 |
| Hamamoto, N | 1 |
| Moritani, M | 1 |
| Mak, R | 1 |
| Ishihara, S | 1 |
| Adachi, K | 1 |
| Kawauchi, H | 1 |
| Kinoshita, Y | 1 |
| Arik, N | 1 |
| Arinsoy, T | 1 |
| Sayín, M | 1 |
| Taşdemir, I | 1 |
| Yasavul, U | 1 |
| Turgan, C | 1 |
| Caglar, S | 1 |
2 other studies available for famotidine and Hyperparathyroidism
| Article | Year |
|---|---|
Primary hyperparathyroidism with duodenal ulcer and H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenoma; Aged; Anti-Ulcer Agents; Benzimidazoles; Duodenal | 2002 |
Famotidine reduces serum parathyroid hormone levels in uremic patients.
Topics: Alkaline Phosphatase; Calcium; Famotidine; Humans; Hyperparathyroidism; Parathyroid Hormone; Phospha | 1991 |